Investors in Viva In Vitro

Today we received the visit of private investors to know the first spinoff of the Murcian Institute of Bio-health Research (IMIB, by its initials in Spanish). Viva In Vitro will develop a novel device for the prognosis of abdominal sepsis, the leading cause of in-hospital mortality. It is based on the discoveries the Molecular Inflammation Group made on the mechanisms of activation of the inflammasome nlrp3. This group is led by the University of Murcia professor Dr. Pablo Pelegrín.

Foundation for Health Research and Training in the Region of Murcia